Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03381586 · ClinicalTrials.gov registry record · Phase 1
QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803
A Phase 1 study, sponsored by Altor BioScience.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT03381586 is a Phase 1 study that has completed, run by Altor BioScience. The registered enrollment target is 20 participants.
The verdict
NCT03381586, a Phase 1 study, has completed, sponsored by Altor BioScience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a single center, open-label, pharmacokinetic study of ALT-803 administered as a subQ injection to healthy volunteers.
Interventions
- DRUG ALT-803
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-12-27 |
| Est. Completion | 2018-03-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03381586
The ClinicalTrials.gov registry entry for NCT03381586 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Altor BioScience, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ALT-803 is the first listed.
NCT03381586 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03381586 about?
NCT03381586 is a clinical study titled "QUILT-1.004: A Single Center, Open-label, Pharmacokinetic Study of Subcutaneous ALT-803". This is a single center, open-label, pharmacokinetic study of ALT-803 administered as a subQ injection to healthy volunteers.
What is the current status of trial NCT03381586?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-12-27. Estimated completion is 2018-03-13.
What interventions are being tested in trial NCT03381586?
The interventions under investigation include: ALT-803 (DRUG).
Who is sponsoring clinical trial NCT03381586?
This trial is sponsored by Altor BioScience, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.